Seeking Alpha

Seattle Genetics (SGEN +4.4%) surges after RBC's Jason Kantor boosts his 2011 and 2012 sales...

Seattle Genetics (SGEN +4.4%) surges after RBC's Jason Kantor boosts his 2011 and 2012 sales forecasts for the company's recently-approved Adcetris drug for treating lymphoma. Kantor claims an RBC survey of 100 hematologists suggests "rapid early adoption" of Adcetris.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs